Nicotinamide N-methyltransferase (NNMT) is a S-adenosyl-L-methionine (SAM) dependent cytoplasm enzyme,which plays a vital role in the biotransformation and detoxification of many drugs and xenobiotic compounds.Recent studies have revealed abnormal expression of NNMT in many tumors,which may contribute to tumorigenesis and tumor development and radiotherapy or chemotherapy resistance.

Objective To study the effects of Alprosladil and Glutathione therapy on patients with drug-induced acute renal damage. Methods 108 patients with drug-induced acute renal damage were divided into three groups at random. The patients in gruoup A (n=36) received 10?g Alprosladil injection once a day, the patients in group B (n=42) received both 10?g alprosladi and 1200mg glutathione injection once a day additionally, and the patients in group C (n=30) received 10mg dpamine injection once a day. The course of treatment of the three groups was 2～4 weeks. Results The effective rates for acute renal failure in groups A, B and C were 85 7%, 96% and 61% respectively. The effective rates for proteinuria, hematuria, N-acetyl-?-glucosaminidase(NAG)and retinol-binding protein(RBP) in urine were 70%, 78%, 76% and 80% in group A, 85%, 90%, 90% and 90% in group B, and 50%, 50%, 42% and 58% in group C respectively, which had significant difference among the three groups (P

OBJECTIVE: To detect the expression of Raf kinase inhibitor protein (RKIP) and epithelial cadherin (E-cadherin) in human prostate cancer tissues, and their correlation. METHODS: We discussed the relationship between RKIP and E-cadherin and the clinical stage and pathological classification of prostate cancer by immunofluorescence histochemistry staining in the test of expression of RKIP in 26 prostate cancer tissues and 14 BPH tissues, and analyzed the correlation between them. RESULTS: The expression of RKIP and E-cadherin in prostate cancer tissues was obviously lower than that in the benign prostatic hypertrophy tissues. The expression of RKIP and E-cadherin in the dys-good differentiation group (Gleason 8-10) was significantly lower than that in the good differentiation group(GleasonCONCLUSION RKIP and E-cadherin are metastasis suppressor factors, whose decreased expression can increase the invasive capability of prostate cancer and suppress its differentiation. RKIP can suppress the metastasis of prostate cancer by increasing the E-cadherin expression in prostate cancer.
Adenocarcinoma ; metabolism ; pathology ; Aged ; Aged, 80 and over ; Cadherins ; genetics ; metabolism ; Fluorescent Antibody Technique ; Humans ; Male ; Middle Aged ; Neoplasm Metastasis ; Phosphatidylethanolamine Binding Protein ; genetics ; metabolism ; Prostatic Neoplasms ; metabolism ; pathology

OBJECTIVE: To analyze the clinical features of benign prostate hyperplasia (BPH) with prostatitis and the role of prostatitis in progression of BPH. METHODS: From July 2003 to Feb. 2009, 466 patients diagnosed BPH were enrolled in this study. Several items including age, history, IPSS, volume of prostate, prostatic special antigen (PSA) and related parameters, Qmax, acute urinary retention (AUR) and the way of treatment were analyzed. RESULTS: A total of 423 patients were diagnosed as BPH with prostatitis (90.77%, PS/BPH group), and 43 were BPH without prostatitis (9.23%, BPH group). Compared with the BPH group, patient's history of the PS/BPH group was longer, IPSS/QOL was increased, the volume of total prostate and transitional zone were larger, maximum flow rate was decreased and risk of AUR was increased, and the proportion of BPH-related surgery was higher.There was no significant difference in patient's age, tPSA, fPSA, f/tPSA, and PSAD between the 2 groups. CONCLUSION Prostatitis may be one etiological factor for BPH. Patients with inflammation were more likely to progress clinically in terms of lower urinary tract symptoms (LUTS), acute urinary retention (AUR), or BPH-related surgery.
Aged ; Humans ; Male ; Middle Aged ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; complications ; diagnosis ; surgery ; Prostatitis ; complications ; diagnosis ; Retrospective Studies ; Urinary Retention ; etiology

OBJECTIVE: To investigate the timing of reaching maximum improvement of the lower urinary tract symptoms (LUTS) in patients with advanced prostate cancer treated with maximal androgen blockade(MAB), and to provide guidelines for the treatment program. METHODS: We collected the data of 45 advanced prostate cancer patients complicated with lower urinary tract symptoms who were treated by MAB. The international prostate symptom score (IPSS) and maximum urinary flow rate (Qmax) were selected as indicators reflecting the degree of lower urinary tract symptoms and were observed before the MAB, 3, 6, and 9 months after the patients received MAB. We also observed the changes of prostate volume and analyzed the role of MAB in improving LUTS in patients with prostate cancer. RESULTS: The IPSS and Qmax had significant difference between the 3rd month after the patients received MAB and before the MAB (P<0.05). No significant difference was found between the 3rd month and the 6th month after the patients received MAB (P>0.05). The prostate volume had significant difference in the 3rd month and the 6th month (P<0.05), but no significant difference in the 6th month and the 9th month (P>0.05). CONCLUSION MAB for patients with advanced prostate cancer can improve their lower urinary tract symptoms, whose main effect is presented in the 3rd months after the androgen deprivation therapy.
Aged ; Aged, 80 and over ; Androgen Antagonists ; therapeutic use ; Anilides ; therapeutic use ; Flutamide ; therapeutic use ; Humans ; Male ; Middle Aged ; Neoplasm Staging ; Nitriles ; therapeutic use ; Prostatic Neoplasms ; complications ; drug therapy ; Tosyl Compounds ; therapeutic use ; Urination Disorders ; drug therapy ; etiology

OBJECTIVE: To explore the clinical features of acute urine retention (AUR) ocurring in patients with benign prostate hyperplasia (BPH). METHODS: Clinical data from 548 patients diagnosed with BPH were retrospectively studied, and the clinical parameters of these patients with or without AUR were analyzed by statistical methods. RESULTS: Development of AUR was found in 164 patients (29.9%). Patients' age, IPSS, maximum flow rate (Q(max)), residual urine volume, prostate volume, transition zone volume, prostate-specific antigen (PSA) density, total PSA (tPSA) and free PSA (fPSA) including the ratio of free to total PSA(f/tPSA) were significantly different in the 2 groups (P<0.05), while there were no significant differences in the disease duration and transition zone index between the 2 groups (P>0.05). Multivariate logistic regression analysis showed that IPSS score, residual urine volume, tPSA, and Q(max) were risk factors for predicting the development of AUR. CONCLUSION BPH patient's age, IPSS, Q(max), residual urine volume, prostate volume, transition zone volume, tPSA and fPSA, and PSA density all influence the occurrence of AUR, in which symptom severity, residual urine volume, total PSA and Q(max) are the principal risk factors for prognosing AUR.
Adult ; Age Factors ; Aged ; Aged, 80 and over ; Humans ; Male ; Middle Aged ; Prostate-Specific Antigen ; blood ; Prostatic Hyperplasia ; complications ; pathology ; Retrospective Studies ; Risk Factors ; Urinary Retention ; epidemiology ; etiology